News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

March 7, 2013

Construction Work Commenced for Drug Product Manufacturing Facility at Takasaki Plant

Tokyo, Japan, March 7, 2013-Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") will commence construction of its HA5 Plant at the Takasaki Plant (Takasaki city, Gunma, Plant Manager: Shohachi Nakajima) in May 2013.

As a part of its production site reorganization, the manufacture of some products currently made at the Fuji Plant (Suntou-gun, Shizuoka) will be transferred to the new HA5 Plant. In addition to these production transfers, the new HA5 Plant is also scheduled to manufacture those drug products currently produced at the Takasaki Plant's existing drug manufacturing facility, as well as new products that the company will hereafter develop. The HA5 Plant is designed for efficient manufacture of multiple products, with a focus on biopharmaceutical injection drugs. It will comply with the Good Manufacturing Practices (GMP) for European, U.S., and Japanese drug products, and will thus be able to supply products globally. The HA5 Plant also has been built to be base isolated system and has an emergency power supply to ensure continued operation in the event of a natural disaster. It will start operation in 2016, and begin commercial production in 2017.

Kyowa Hakko Kirin will continue to strengthen its production system to ensure the stable supply of high-quality pharmaceutical products to patients.



New plant overview
Plant name: HA5 Plant
Scale: Four stories, with total floor space of approx. 4106 m2. Built with steel frame
Investment: Approx. 4.6 billion yen
Purpose: Manufacture of injection drugs
Completion: Second quarter, 2014 (April to June)
Start of operations: 2016
Launch of commercial production: 2017
Characteristics: (1) Able to manufacture multiple products, with a focus on biopharmaceutical drugs in freeze-dried and liquid form.
(2) Complies with GMP in Japan, the US, and the EU.
(3) Base isolated system and emergency power supply system.

Contact:

Kyowa Hakko Kirin
Media Contact:
+81-3-3282-1903
or
Investors:
+81-3-3282-0009



To Page Top